Bispecifics come of age: how preclinical tools are helping drive translation to the clinic

Immuno-Oncology Insights 2022; 3(8), 331–337

DOI: 10.18609/ioi.2021.033

Published: 19 June 2022
Michelle Morrow

Michelle Morrow of F-star Therapeutics discusses the company’s unique approach to creating bispecifics, the evolution of the bispecifics field, and new and emerging nonclinical tools for I-O applications.

Michelle Morrow PhD, is Senior Vice President of Biology & Translational Sciences at F-star Therapeutics, overseeing the company’s biology and translational sciences teams’ research activities ranging from discovery through to clinical phase programs. Major achievements during this time include progressing FS118, FS120 and FS222 from candidate selection into the clinic. She also plays a key role as a Project Leader for FS118, a LAG-3/PD-L1 bispecific antibody in Phase 2 clinical trials. Michelle joined F-star from MedImmune, where she was a Project and Team Leader from 2007 to 2017, and she successfully established an immuno–oncology preclinical modelling group, supporting projects across the MedImmune and AstraZeneca portfolio. She led research project teams for several novel therapies within the Oncology portfolio, including FDA-approved ImfinziTM (durvalumab) and MEDI5752 (PD-1/CTLA-4 bispecific). Michelle earned a PhD in Immunology at the University of Cambridge and completed her post-doctoral studies in leukemia research at the Institute of Child Health, London.